Anthony Opipari
Net worth: 183 949 $ as of 31/08/2026
Net worth: 183 949 $ as of 31/08/2026
Anthony Opipari was the founder of First Wave Bio, Inc., founded in 2021, IFM Therapeutics LLC, founded in 2021, and Lycera Corp., founded in 2006 where Dr. Opipari held the title of Senior Director-Biology from 2006 to 2021.
Dr. Opipari currently holds the position of Chief Medical Officer & EVP-Translational Medicine at Odyssey Therapeutics, Inc. since 2024.
Dr. Opipari earned a doctorate degree from the University of Michigan.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 11/05/2026 | 7,502 ( 0.02% ) | 183 949 $ | 31/08/2026 |
| Companies | Position | Start |
|---|---|---|
| ODYSSEY THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 01/04/2021 |
| Companies | Position | End |
|---|---|---|
Lycera Corp.
Lycera Corp. Pharmaceuticals: MajorHealth Technology Develops novel oral medicines for treating autoimmune diseases and cancer | Founder | 01/01/2021 |
IFM Therapeutics LLC
IFM Therapeutics LLC Pharmaceuticals: MajorHealth Technology Discovers and develops small molecules that modulate novel targets in the innate immune system as next generation therapies for cancer, autoimmunity and inflammatory disorders | Founder | - |
First Wave Bio, Inc.
First Wave Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Develops novel therapeutics for the treatment of inflammatory bowel disease | Founder | - |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 5 |
|---|---|
Lycera Corp.
Lycera Corp. Pharmaceuticals: MajorHealth Technology Develops novel oral medicines for treating autoimmune diseases and cancer | Health Technology |
University of Michigan
University of Michigan Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
IFM Therapeutics LLC
IFM Therapeutics LLC Pharmaceuticals: MajorHealth Technology Discovers and develops small molecules that modulate novel targets in the innate immune system as next generation therapies for cancer, autoimmunity and inflammatory disorders | Health Technology |
First Wave Bio, Inc.
First Wave Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Develops novel therapeutics for the treatment of inflammatory bowel disease | Commercial Services |
Odyssey Therapeutics, Inc.
Odyssey Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company that develops therapeutics for autoimmune and inflammatory diseases | Health Technology |
Select your edition
All financial news and data tailored to specific country editions